Asian Journal of Pharmacy and Technology

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

The Design of Liposomal Vaccine Adjuvant


Affiliations
1 Department of Pharmaceutics, Airlangga University. Jalan Dharmawangsa Dalam, 60286 Surabaya, Indonesia
     

   Subscribe/Renew Journal


Vaccines are still the most effective way of preventing infectious diseases. Through vaccination, the immune system is exposed to the antigen so that its response will increase in subsequent exposure. Liposomes were first reported as a vaccine carrier in 1974 by Allison and Gregoriardis. Liposomes are chosen as carriers in a vaccine delivery system because they are made from natural, biodegradable, nontoxic and non-immunogenic phospholipids. The effectiveness of liposome formulation depends on various physicochemical factors such as vesicle size, surface charge, bilayer composition, coating, route of administration, adjuvant usage, encapsulation efficiency, and ultimately dependent on the lipid composition used. DDA (dietildioctadecylammonium) is one of the major lipid components in the vaccine adjuvant system because of its cationic nature, but DDA has a weakness in terms of its physical stability. The addition of cholesterol in the liposome composition may improve lipid packing thereby reducing or eliminating the phase transition temperature of the liposome system. APC contains many molecules expressed on the cell surface, which can be utilized in facilitating specific liposome targeting.

Keywords

Liposome, Adjuvant, Vaccine, DDA, Formulation.
Subscription Login to verify subscription
User
Notifications
Font Size


  • Andrews CD. Multicomponent Vaccine Delivery Systems for Subcellular Targeting of Antigen and Molecular Adjuvant. 2011.

  • Perrie Y, Crofts F, Devitt A, Griffiths HR, Kastner E, Nadella V. Designing liposomal adjuvants for the next generation of vaccines. Adv Drug Deliv Rev. November 2015. doi:10.1016/j.addr.2015.11.005.

  • Brito LA, Malyala P, O’Hagan DT. Vaccine adjuvant formulations: A pharmaceutical perspective. Semin Immunol. 2013;25 (2):130-145. doi:10.1016/j.smim.2013.05.007.

  • Shakya AK, Nandakumar KS. New Generation Vaccines: Need for Safe and Improved Adjuvants. In: Vaccines and Vaccine Technologies. USA: Foster City: OMICS Group eBooks; 2015:77-90.

  • Giddam AK, Zaman M, Skwarczynski M, Toth I. Liposome-based delivery system for vaccine candidates: constructing an effective formulation. Nanomed. 2012;7(12) :1877-1893. doi:10.2217/nnm.12.157.

  • Kojima N, Ishii M, Kawauchi Y, Takagi H. Oligomannose-Coated Liposome as a Novel Adjuvant for the Induction of Cellular Immune Responses to Control Disease Status. BioMed Res Int. 2013;2013:1-11. doi:10.1155/2013/562924.

  • Wilkinson A. Nanotechnology for the delivery of vaccines. January 2014. http://eprints.aston.ac.uk/21411/. Accessed March 12, 2016.

  • Hossann M, Syunyaeva Z, Schmidt R, et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Controlled Release. 2012;162 (2):400-406. doi:10.1016/j.jconrel.2012.06.032.

  • Holten-Andersen L, Doherty TM, Korsholm KS, Andersen P. Combination of the Cationic Surfactant Dimethyl Dioctadecyl Ammonium Bromide and Synthetic Mycobacterial Cord Factor as an Efficient Adjuvant for Tuberculosis Subunit Vaccines. Infect Immun. 2004;72(3):1608-1617. doi:10.1128/IAI.72.3.1608-1617.2004.

  • Kett V, Yusuf H, McCarthy H, Chen KH. Liposomal delivery system. March 2015. http://www.google.ch/patents/US20150079156. Accessed August 25, 2016.

  • Kaur R, Henriksen-Lacey M, Wilkhu J, Devitt A, Christensen D, Perrie Y. Effect of Incorporating Cholesterol into DDA:TDB Liposomal Adjuvants on Bilayer Properties, Biodistribution, and Immune Responses. Mol Pharm. 2014;11(1):197-207. doi:10.1021/mp400372j.

  • Smith Korsholm K, Agger EM, Foged C, et al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology. 2007;121(2):216-226. doi:10.1111/j. 1365-2567.2007. 02560.x.

  • Perrie Y, Kastner E, Kaur R, Wilkinson A, Ingham AJ. A case-study investigating the physicochemical characteristics that dictate the function of a liposomal adjuvant. Hum Vaccines Immunother. 2013;9(6):1374-1381. doi:10.4161/hv.24694.

  • Liu X, Da Z, Wang Y, et al. A novel liposome adjuvant DPC mediates Mycobacterium tuberculosis subunit vaccine well to induce cell-mediated immunity and high protective efficacy in mice. Vaccine. 2016;34(11):1370-1378. doi:10.1016/j. vaccine. 2016.01.049.

  • Ishii M, Kato C, Hakamata A, Kojima N. Targeting with oligomannose-coated liposomes promotes maturation and splenic trafficking of dendritic cells in the peritoneal cavity. Int Immuno pharmacol. 2011; 11(2):164-171. doi:10.1016/j.intimp.2010.11.011.


Abstract Views: 227

PDF Views: 0




  • The Design of Liposomal Vaccine Adjuvant

Abstract Views: 227  |  PDF Views: 0

Authors

Raditya Weka Nugraheni
Department of Pharmaceutics, Airlangga University. Jalan Dharmawangsa Dalam, 60286 Surabaya, Indonesia
Helmy Yusuf
Department of Pharmaceutics, Airlangga University. Jalan Dharmawangsa Dalam, 60286 Surabaya, Indonesia
Dwi Setyawan
Department of Pharmaceutics, Airlangga University. Jalan Dharmawangsa Dalam, 60286 Surabaya, Indonesia

Abstract


Vaccines are still the most effective way of preventing infectious diseases. Through vaccination, the immune system is exposed to the antigen so that its response will increase in subsequent exposure. Liposomes were first reported as a vaccine carrier in 1974 by Allison and Gregoriardis. Liposomes are chosen as carriers in a vaccine delivery system because they are made from natural, biodegradable, nontoxic and non-immunogenic phospholipids. The effectiveness of liposome formulation depends on various physicochemical factors such as vesicle size, surface charge, bilayer composition, coating, route of administration, adjuvant usage, encapsulation efficiency, and ultimately dependent on the lipid composition used. DDA (dietildioctadecylammonium) is one of the major lipid components in the vaccine adjuvant system because of its cationic nature, but DDA has a weakness in terms of its physical stability. The addition of cholesterol in the liposome composition may improve lipid packing thereby reducing or eliminating the phase transition temperature of the liposome system. APC contains many molecules expressed on the cell surface, which can be utilized in facilitating specific liposome targeting.

Keywords


Liposome, Adjuvant, Vaccine, DDA, Formulation.

References